Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Completes Target Enrollment in the TH-302 Phase 3 MAESTRO Study in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma

SOUTH SAN FRANCISCO, CA--(Marketwired - Nov 3, 2014) - Threshold Pharmaceuticals, Inc. ( NASDAQ : THLD ), today announced that Threshold's partner Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, has completed target enrollment of 660 patients in the global Phase 3 MAESTRO ( M etast A tic or unr ES ectable pancrea T ic adenocarcinoma) study assessing the efficacy and safety of TH-302 in combination with gemcitabine in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma. Threshold has a global license and co-development agreement with Merck KGaA, Darmstadt, Germany for TH-302, which includes an option for Threshold to co-commercialize in the U.S.

"The MAESTRO trial of TH-302 for patients with advanced pancreatic cancer is the second of two pivotal Phase 3 trials of TH-302 to complete enrollment, the first being our trial for previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma," said Barry Selick, Ph.D., Chief Executive Officer of Threshold. "We are pleased to have completed enrollment in both trials. We anticipate conducting the primary analysis of overall survival for our Phase 3 trial in patients with advanced soft tissue sarcoma in the first quarter of 2016 and having top-line data for MAESTRO in 2016."

MAESTRO is a randomized, placebo-controlled, international, multi-center, double-blind Phase 3 trial of TH-302 plus gemcitabine compared with placebo plus gemcitabine. The primary efficacy endpoint is overall survival; the secondary endpoints include efficacy measured by progression-free survival (PFS), overall response rate and disease control rate, as well as assessments of safety and tolerability, pharmacokinetics and biomarkers. The study is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). The study design was also discussed with the European Medicines Agency (EMA) during a scientific advice procedure.

About Pancreatic Cancer It is estimated that 337,872 cases of pancreatic cancer are diagnosed worldwide every year, accounting for 2.4% of all cancers. 1 Almost 67% of cases are diagnosed in people aged 65 and over; it is uncommon in people under the age of 45. 2 Pancreatic cancer has a low survival rate regardless of stage of disease, with 93% of patients dying from their disease within 5 years. 2 It is estimated that there are 330,372 deaths from pancreatic cancer worldwide each year. 1

About TH-302 TH-302, an investigational hypoxia-activated prodrug, is designed to be activated under severe tumor hypoxic conditions, a hallmark of many cancers. Areas of low oxygen levels (hypoxia) in solid tumors are due to insufficient blood supply as a result of aberrant vasculature. Similarly, the bone marrow of patients with hematological malignancies has also been shown, in some cases, to be severely hypoxic.

TH-302 is currently under evaluation in two Phase 3 trials: one in combination with doxorubicin versus doxorubicin alone in patients with locally advanced unresectable or metastatic soft tissue sarcoma (STS), and the other in combination with gemcitabine versus gemcitabine and placebo in patients with advanced pancreatic cancer (the MAESTRO trial). Both Phase 3 trials are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. The FDA and the European Commission have granted TH-302 Orphan Drug Designation for the treatment of STS and pancreatic cancer. TH-302 is also being investigated in earlier-stage clinical trials of other solid tumors and hematological malignancies.

Threshold has a global license and co-development agreement for TH-302 with Merck KGaA, Darmstadt, Germany, which includes an option for Threshold to co-commercialize in the U.S.

About Threshold Pharmaceuticals Threshold Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of drugs targeting tumor hypoxia, the low oxygen condition found in the microenvironments of most solid tumors as well as the bone marrows of some patients with hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website ( www.thresholdpharm.com ).

References

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr , accessed on October 31, 2014. 2. National Cancer Institute Surveillance Epidemiology and End Results (SEER). Available at http://seer.cancer.gov/statfacts/html/pancreas.html . Last accessed: October 31, 2014.

Forward-Looking Statements

Except for statements of historical fact, the statements in this press release are forward-looking statements, including all statements regarding the anticipated timing for top-line data for the MAESTRO trial, the anticipated timing of the primary analysis of overall survival for Threshold's Phase 3 clinical trial of TH-302 in patients with advanced STS, or the 406 trial, and the potential therapeutic uses and benefits of TH-302 to treat patients with advanced STS, advanced pancreatic cancer and other cancers. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to: the ability of Threshold and Merck KGaA, Darmstadt, Germany, to complete TH-302 clinical trials, including the MAESTRO trial and the 406 trial; the time and expense required to conduct such clinical trials and analyze data; the risk that because the timing of the top-line results of the MAESTRO trial and the timing of the primary efficacy analysis for the 406 trial is driven by the number of events in each trial, which neither Threshold nor Merck KGaA, Darmstadt, Germany, controls, Threshold cannot predict with certainty when these events will occur; issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and interpretation of efficacy results by regulatory authorities); the risk that later trials, including either the MAESTRO trial or the 406 trial, may not confirm the results of earlier trials; the risk that the design of, or data collected from, the MAESTRO trial and the 406 trial may be inadequate to demonstrate safety and efficacy, or otherwise may be insufficient to support regulatory submissions and/or approvals, and that despite the potential benefits of SPA agreements with the FDA, significant uncertainty remains regarding the regulatory approval process for TH-302 and that TH-302 may not receive any marketing approvals for the advanced STS or advanced pancreatic cancer indication, or in any other indications, in a timely manner or at all; Threshold's and Merck KGaA's (Darmstadt, Germany) dependence on single source suppliers, including the risk that these single source suppliers may be unable to meet clinical supply demands for TH-302 which could significantly delay the development of TH-302; risks related to Threshold's dependence on its collaborative relationship with Merck KGaA, Darmstadt, Germany, including its dependence on decisions by Merck KGaA, Darmstadt, Germany regarding the amount and timing of resource expenditures for the development of TH-302; and Threshold's need for and the availability of resources to develop TH-302 and to support Threshold's operations. Further information regarding these and other risks is included under the heading "Risk Factors" in Exhibit 99.1 to Threshold's Current Report on Form 8-K, which has been filed with the Securities and Exchange Commission on October 9, 2014 and is available from the SEC's website ( www.sec.gov ) and on our website ( www.thresholdpharm.com ) under the heading "Investors." We undertake no duty to update any forward-looking statement made in this news release.

Contact Laura Hansen, Ph.D. Senior Director, Corporate Communications Phone: 650-474-8206 E-mail: lhansen@thresholdpharm.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Illumina's Virtual Cell Win Raises Bigger AI Stakes

Updated Category News Views 54

A blind prediction contest is a useful place to separate glossy AI talk from actual biology. Illumina's BioInsight AI Lab took first place in Arc Institute's 2026 Virtual Cell Challenge, outperforming roughly 1,500 competitors on predictions of how cells would react when genes were knocked down. That is not a quarterly revenue number, and nobody should pretend otherwise....

Continue Reading
AI Shopping Answers Are Becoming Retail's New Shelf

Updated Category News Views 6

Retail’s front door is quietly being moved by a machine, and plenty of big chains appear to be staring at the old entrance. Bain’s latest work lands on an uncomfortable point: owning market share does not guarantee a retailer gets named when an AI assistant answers a shopper’s question. That ought to rattle management teams more than the usual holiday-season...

Continue Reading
Fromm Day Marks 50 Years of Learning and Connection

Updated Category News Views 65

A city proclamation can be fluffy civic confetti, but this one lands differently. San Francisco declared Nov. 14, 2026, Fromm Day as the Fromm Institute for Lifelong Learning marked its 50th anniversary, and the underlying story is sturdier than a ceremonial photo op. A program that began in 1976 expecting roughly 50 people at an open house drew about 150 students in its...

Continue Reading
PenFed’s Toys for Tots Drive Targets Holiday Gift Gaps

Updated Category News Views 116

A missing present under a tree is not a statistic anybody ought to glide past. PenFed Credit Union has opened its annual Toys for Tots collection across Washington-region branches, taking new, unwrapped toys through December 8 at 1:00 p.m. ET. The useful detail, and frankly the one worth remembering when people default to buying the easiest shiny thing on a shelf, is...

Continue Reading
A. O. Smith's Sustainability Scorecard Has Real Teeth

Updated Category News Views 130

Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...

Continue Reading
AIM Academy Accreditation Signals a Broader Quality Push

Updated Category News Views 50

Early-childhood education does not hand out many clean, easily comparable scorecards, which is precisely why AIM Academy’s new Cognia recognition deserves a closer look. The Alabama provider has earned Cognia Initial Accreditation, while its Pike Road center received Accreditation with Merit after its Initial Accreditation Review. That is not a revenue event, not a...

Continue Reading
DHC’s Ulta Rollout Gets a Useful Pricing Correction

Updated Category News Views 49

A face-wash price tag just became the most revealing part of DHC’s Ulta expansion. The company corrected an earlier announcement that had listed its new Deep Cleansing Face Wash at $31.50; the actual price is $19.00. That may sound like tiny housekeeping, and in the grand scheme it is, but consumer brands live or die on this kind of detail. A cleanser priced near $20...

Continue Reading
Blast Doubles Athabasca Ground, but Drills Still Matter

Updated Category News Views 75

More ground in Athabasca can wake up a uranium junior fast, and Blast Resources has certainly grabbed investors’ attention with this one. The company has optioned eight additional uranium claims beside its Wales Lake property in northern Saskatchewan, taking its regional footprint from 12,150 hectares across 16 claims to 30,732 hectares across 24 claims. That is more...

Continue Reading
Fresha Pushes Beauty Bookings Into AI Search Channels

Updated Category News Views 80

A haircut search is turning into a distribution fight, and Fresha has planted itself squarely in the middle of it. The company’s new Partner Network pushes its beauty and wellness marketplace beyond its own app and website into Google Search, Google Maps, Google’s AI experiences, ChatGPT, Claude, and eventually Alexa. That sounds like another glossy AI announcement...

Continue Reading
IT Tech Packaging's Going-Concern Warning Lands Hard

Updated Category News Views 91

A paper maker can survive plenty of ugly quarters; it cannot casually shrug off an auditor questioning whether it can keep operating. That is the cold part of IT Tech Packaging's Nov. 19 disclosure. Its newly filed Form 10-K for the year ended Dec. 31, 2025 carries a “Material Uncertainty Related to Going Concern” paragraph from Audit Alliance LLP. Nobody should dress...

Continue Reading

Top 5 Most Recently Viewed Articles

Massimo Group Sees Growth Amid Challenges in Q3 2024

Updated Category News Views 362

Massimo Group Reports Solid Year-to-Date Revenue Growth Massimo Group (NASDAQ: MAMO) has shared encouraging financial results for the year so far, showcasing a remarkable 20.8% increase in revenue year-over-year (YoY), totaling $91.2 million. This positive trend is largely attributed to the company's innovative production, product enhancements, and effective sales...

Continue Reading
Earnings Preview: What to Expect from Dayforce's Q2 Results

Updated Category News Views 246

Anticipation for Dayforce's Upcoming Earnings Dayforce (NYSE: DAY) is gearing up for its quarterly earnings announcement, which is scheduled for a Wednesday. Investors are eagerly awaiting insights into the company's performance, particularly focusing on earnings surpassing estimates and positive guidance for future quarters. Analyst Expectations Industry analysts predict...

Continue Reading
AutoRABIT CodeScan Enhances Security for AI-Driven Code

Updated Category News Views 71

The Essential Role of AutoRABIT CodeScan in AI Security As artificial intelligence shapes the landscape of software development, it brings both exciting innovations and significant security challenges. AutoRABIT CodeScan stands out as a crucial tool designed to address these vulnerabilities, helping developers work safely with AI-generated code. Exploring the Risks of AI...

Continue Reading
Mythos AI Breaks New Ground in Autonomous Shipping Navigation

Updated Category News Views 240

Mythos AI Achieves Milestone in Autonomous Navigation In a groundbreaking achievement, Mythos AI has successfully surpassed 11,000 miles of fully autonomous navigation, marking a significant advancement in shipping technology. The company's AI-driven navigation system not only exceeds military-grade capabilities in safety and operational efficiency but also sets a new...

Continue Reading
Explore the Rich Tapestry of Michigan's Harvest Season

Updated Category News Views 218

Experience Michigan's Harvest Season As autumn settles in, Michigan transforms into a breathtaking landscape filled with vibrant colors and rich traditions. This time of year, the state's famous agriculture thrives, creating an atmosphere that beckons travelers to experience the harvest season to the fullest. From golden fields of corn to sprawling orchards full of ripe...

Continue Reading